218 related articles for article (PubMed ID: 27010855)
21. Theanine from tea and its semi-synthetic derivative TBrC suppress human cervical cancer growth and migration by inhibiting EGFR/Met-Akt/NF-κB signaling.
Liu J; Sun Y; Zhang H; Ji D; Wu F; Tian H; Liu K; Zhang Y; Wu B; Zhang G
Eur J Pharmacol; 2016 Nov; 791():297-307. PubMed ID: 27612630
[TBL] [Abstract][Full Text] [Related]
22. Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice.
Wang D; Fu L; Sun H; Guo L; DuBois RN
Gastroenterology; 2015 Dec; 149(7):1884-1895.e4. PubMed ID: 26261008
[TBL] [Abstract][Full Text] [Related]
23. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
24. Roles of prostaglandin E2-EP3/EP4 receptor signaling in the enhancement of lymphangiogenesis during fibroblast growth factor-2-induced granulation formation.
Hosono K; Suzuki T; Tamaki H; Sakagami H; Hayashi I; Narumiya S; Alitalo K; Majima M
Arterioscler Thromb Vasc Biol; 2011 May; 31(5):1049-58. PubMed ID: 21311040
[TBL] [Abstract][Full Text] [Related]
25. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
[TBL] [Abstract][Full Text] [Related]
26. PGE2 promotes breast cancer-associated lymphangiogenesis by activation of EP4 receptor on lymphatic endothelial cells.
Nandi P; Girish GV; Majumder M; Xin X; Tutunea-Fatan E; Lala PK
BMC Cancer; 2017 Jan; 17(1):11. PubMed ID: 28056899
[TBL] [Abstract][Full Text] [Related]
27. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone promoted gastric cancer growth through prostaglandin E receptor (EP2 and EP4) in vivo and in vitro.
Shin VY; Jin HC; Ng EK; Cho CH; Leung WK; Sung JJ; Chu KM
Cancer Sci; 2011 May; 102(5):926-33. PubMed ID: 21261791
[TBL] [Abstract][Full Text] [Related]
28. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
29. Cordycepin inhibits lipopolysaccharide-induced cell migration and invasion in human colorectal carcinoma HCT-116 cells through down-regulation of prostaglandin E2 receptor EP4.
Jeong JW; Park C; Cha HJ; Hong SH; Park SH; Kim GY; Kim WJ; Kim CH; Song KS; Choi YH
BMB Rep; 2018 Oct; 51(10):532-537. PubMed ID: 30269738
[TBL] [Abstract][Full Text] [Related]
30. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation.
Schlange T; Matsuda Y; Lienhard S; Huber A; Hynes NE
Breast Cancer Res; 2007; 9(5):R63. PubMed ID: 17897439
[TBL] [Abstract][Full Text] [Related]
31. PGE
Lin MC; Chen SY; He PL; Herschman H; Li HJ
Int J Cancer; 2018 Sep; 143(6):1440-1455. PubMed ID: 29658109
[TBL] [Abstract][Full Text] [Related]
32. COX-2 Elevates Oncogenic miR-526b in Breast Cancer by EP4 Activation.
Majumder M; Landman E; Liu L; Hess D; Lala PK
Mol Cancer Res; 2015 Jun; 13(6):1022-33. PubMed ID: 25733698
[TBL] [Abstract][Full Text] [Related]
33. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F
Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433
[TBL] [Abstract][Full Text] [Related]
34. Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer.
Casagrande N; De Paoli M; Celegato M; Borghese C; Mongiat M; Colombatti A; Aldinucci D
Gynecol Oncol; 2013 Dec; 131(3):744-52. PubMed ID: 24029417
[TBL] [Abstract][Full Text] [Related]
35. Prostaglandin E2 contributes to the synthesis of brain-derived neurotrophic factor in primary sensory neuron in ganglion explant cultures and in a neuropathic pain model.
Cruz Duarte P; St-Jacques B; Ma W
Exp Neurol; 2012 Apr; 234(2):466-81. PubMed ID: 22309829
[TBL] [Abstract][Full Text] [Related]
36. Targeting EP4 by curcumin through cross talks of AMP-dependent kinase alpha and p38 mitogen-activated protein kinase signaling: the role of PGC-1α and Sp1.
Hann SS; Chen J; Wang Z; Wu J; Zheng F; Zhao S
Cell Signal; 2013 Dec; 25(12):2566-74. PubMed ID: 23998949
[TBL] [Abstract][Full Text] [Related]
37. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
[TBL] [Abstract][Full Text] [Related]
38. EP4 as a Therapeutic Target for Aggressive Human Breast Cancer.
Majumder M; Nandi P; Omar A; Ugwuagbo KC; Lala PK
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29596308
[TBL] [Abstract][Full Text] [Related]
39. Calcium-mediated increased expression of fibroblast growth factor-2 acts through NF-κB and PGE2/EP4 receptor signaling pathways in cementoblasts.
Kanaya S; Nemoto E; Sakisaka Y; Shimauchi H
Bone; 2013 Oct; 56(2):398-405. PubMed ID: 23851295
[TBL] [Abstract][Full Text] [Related]
40. Prostaglandin E2 (PGE2) promotes proliferation and invasion by enhancing SUMO-1 activity via EP4 receptor in endometrial cancer.
Ke J; Yang Y; Che Q; Jiang F; Wang H; Chen Z; Zhu M; Tong H; Zhang H; Yan X; Wang X; Wang F; Liu Y; Dai C; Wan X
Tumour Biol; 2016 Sep; 37(9):12203-12211. PubMed ID: 27230680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
